ATAI stock sentiment todayAtaiBeckley Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
ATAI
AtaiBeckley IncA speculative biotech play in the psychedelic medicine space with high cash reserves but significant clinical binary risk.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ATAI. Not financial advice.
Price · last 12 months
Gossip
The market is currently focusing on the 'psychedelic renaissance' in mental health. While ATAI is viewed as a diversified platform leader, sentiment is cautious following MDMA-related regulatory hurdles for the industry and the long timeline for their own lead assets (COMP360 via Compass and BPL-003).
- ·Anticipation of Phase 2b data for BPL-003 (intranasal 5-MeO-DMT)
- ·Regulatory sentiment shifts regarding psychedelic-assisted therapies
- ·Strategic investment and backing by Christian Angermayer and Peter Thiel
Financial
ATAI maintains a robust balance sheet for a clinical-stage biotech, with roughly $270M in cash/marketable securities providing a runway into 2026. However, it is pre-revenue and burning cash to fund its multi-program pipeline.
- ·Cash Runway: Funded into 2026
- ·Market Cap: ~$130M (significant discount to cash value/NAV)
- ·R&D Expense: $50M+ annually
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Clinical failure of lead candidate BPL-003 or VLS-01
- ·FDA regulatory barriers for scheduled substances
- ·Dilution risk if clinical trials extend beyond 2026 runway
Peer temperature
How direct competitors stack up against ATAI right now.
- HOTCMPSCompass Pathways
HOTTER — Further along in clinical development with Phase 3 trials for psilocybin, providing a more immediate catalyst path.
See full analysis → - NEUTRALCYBNCybin Inc.
COLDER — Higher dilution risk recently despite promising deuterated psilocybin data, with a thinner cash cushion than ATAI.
See full analysis → - NEUTRALGHRSGH Research
NEUTRAL — More focused 5-MeO-DMT pure play, but lacks the diversified portfolio and strategic partnership depth of ATAI.
See full analysis →
- ATAI+2.4%
- CMPS-2.3%
- CYBN—
- GHRS-3.1%
Analyst price target
Consensus average of 5 analysts · median 7.50
Source: StockAnalysis.com · updated 2026-08-19
AI-generated analysis for informational purposes only. Not financial advice.